Search tips
Search criteria 


Logo of eidEmerging Infectious Diseases
Emerg Infect Dis. 2001 Mar-Apr; 7(2): 197–199.
PMCID: PMC2631731

New technologies to prevent intravascular catheter-related bloodstream infections.


Most intravascular catheter-related infections are associated with central venous catheters. Technologic advances shown to reduce the risk for these infections include a catheter hub containing an iodinated alcohol solution, short-term chlorhexidine-silver sulfadiazine- impregnated catheters, minocycline-rifampin-impregnated catheters, and chlorhexidine- impregnated sponge dressings. Nontechnologic strategies for reducing risk include maximal barrier precautions during catheter insertion, specialized nursing teams, continuing quality improvement programs, and tunneling of short-term internal jugular catheters.

Full Text

The Full Text of this article is available as a PDF (46K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Richet H, Hubert B, Nitemberg G, Andremont A, Buu-Hoi A, Ourbak P, Galicier C, Veron M, Boisivon A, Bouvier AM, et al. Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. J Clin Microbiol. 1990 Nov;28(11):2520–2525. [PMC free article] [PubMed]
  • Collignon PJ. Intravascular catheter associated sepsis: a common problem. The Australian Study on Intravascular Catheter Associated Sepsis. Med J Aust. 1994 Sep 19;161(6):374–378. [PubMed]
  • Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med. 2000 Mar 7;132(5):391–402. [PubMed]
  • Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med. 1997 Aug 15;127(4):257–266. [PubMed]
  • van Heerden PV, Webb SA, Fong S, Golledge CL, Roberts BL, Thompson WR. Central venous catheters revisited--infection rates and an assessment of the new Fibrin Analysing System brush. Anaesth Intensive Care. 1996 Jun;24(3):330–333. [PubMed]
  • Bach A, Schmidt H, Böttiger B, Schreiber B, Böhrer H, Motsch J, Martin E, Sonntag HG. Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters. J Antimicrob Chemother. 1996 Feb;37(2):315–322. [PubMed]
  • Collin GR. Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continuous quality improvement project. Chest. 1999 Jun;115(6):1632–1640. [PubMed]
  • George SJ, Vuddamalay P, Boscoe MJ. Antiseptic-impregnated central venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients. Eur J Anaesthesiol. 1997 Jul;14(4):428–431. [PubMed]
  • Pemberton LB, Ross V, Cuddy P, Kremer H, Fessler T, McGurk E. No difference in catheter sepsis between standard and antiseptic central venous catheters. A prospective randomized trial. Arch Surg. 1996 Sep;131(9):986–989. [PubMed]
  • Logghe C, Van Ossel C, D'Hoore W, Ezzedine H, Wauters G, Haxhe JJ. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. J Hosp Infect. 1997 Oct;37(2):145–156. [PubMed]
  • Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA. 1999 Aug 11;282(6):554–560. [PubMed]
  • Oda T, Hamasaki J, Kanda N, Mikami K. Anaphylactic shock induced by an antiseptic-coated central venous [correction of nervous] catheter. Anesthesiology. 1997 Nov;87(5):1242–1244. [PubMed]
  • Tattawasart U, Maillard JY, Furr JR, Russell AD. Development of resistance to chlorhexidine diacetate and cetylpyridinium chloride in Pseudomonas stutzeri and changes in antibiotic susceptibility. J Hosp Infect. 1999 Jul;42(3):219–229. [PubMed]
  • Darouiche RO, Raad II, Heard SO, Thornby JI, Wenker OC, Gabrielli A, Berg J, Khardori N, Hanna H, Hachem R, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med. 1999 Jan 7;340(1):1–8. [PubMed]
  • Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, Wall M, Harris R, Jones J, Buzaid A, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med. 1997 Aug 15;127(4):267–274. [PubMed]
  • Segura M, Alvarez-Lerma F, Tellado JM, Jiménez-Ferreres J, Oms L, Rello J, Baró T, Sánchez R, Morera A, Mariscal D, et al. A clinical trial on the prevention of catheter-related sepsis using a new hub model. Ann Surg. 1996 Apr;223(4):363–369. [PubMed]
  • Raad II, Hohn DC, Gilbreath BJ, Suleiman N, Hill LA, Bruso PA, Marts K, Mansfield PF, Bodey GP. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol. 1994 Apr;15(4 Pt 1):231–238. [PubMed]
  • Soifer NE, Borzak S, Edlin BR, Weinstein RA. Prevention of peripheral venous catheter complications with an intravenous therapy team: a randomized controlled trial. Arch Intern Med. 1998 Mar 9;158(5):473–477. [PubMed]
  • Sherertz RJ, Ely EW, Westbrook DM, Gledhill KS, Streed SA, Kiger B, Flynn L, Hayes S, Strong S, Cruz J, et al. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med. 2000 Apr 18;132(8):641–648. [PubMed]
  • Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet. 2000 May 27;355(9218):1864–1868. [PubMed]
  • Maas A, Flament P, Pardou A, Deplano A, Dramaix M, Struelens MJ. Central venous catheter-related bacteraemia in critically ill neonates: risk factors and impact of a prevention programme. J Hosp Infect. 1998 Nov;40(3):211–224. [PubMed]
  • Timsit JF, Sebille V, Farkas JC, Misset B, Martin JB, Chevret S, Carlet J. Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study. JAMA. 1996 Nov 6;276(17):1416–1420. [PubMed]
  • Vaudaux P, Pittet D, Haeberli A, Lerch PG, Morgenthaler JJ, Proctor RA, Waldvogel FA, Lew DP. Fibronectin is more active than fibrin or fibrinogen in promoting Staphylococcus aureus adherence to inserted intravascular catheters. J Infect Dis. 1993 Mar;167(3):633–641. [PubMed]
  • Huesca M, Sun Q, Peralta R, Shivji GM, Sauder DN, McGavin MJ. Synthetic peptide immunogens elicit polyclonal and monoclonal antibodies specific for linear epitopes in the D motifs of Staphylococcus aureus fibronectin-binding protein, which are composed of amino acids that are essential for fibronectin binding. Infect Immun. 2000 Mar;68(3):1156–1163. [PMC free article] [PubMed]
  • Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998 Apr 10;280(5361):295–298. [PubMed]
  • Parsek MR, Val DL, Hanzelka BL, Cronan JE, Jr, Greenberg EP. Acyl homoserine-lactone quorum-sensing signal generation. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4360–4365. [PubMed]
  • Otto M, Süssmuth R, Vuong C, Jung G, Götz F. Inhibition of virulence factor expression in Staphylococcus aureus by the Staphylococcus epidermidis agr pheromone and derivatives. FEBS Lett. 1999 May 7;450(3):257–262. [PubMed]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention